> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# 6 Observations in Lupin Nagpur Inspection
- URL: https://www.fdaweb.com/6-observations-in-lupin-nagpur-inspection/
- Published: 2026-01-22T12:00:00.000Z
- Updated: 2026-09-14T15:31:19.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5160527

FDA has released the form FDA-483 with six observations from a 9/8-9/16/2025 inspection at the Lupin sterile manufacturing facility in Nagpur, Maharashtra, India. The observations were:

- failure of procedures designed to prevent microbiological contamination of drug products purporting to be sterile to include adequate validation of the aseptic and sterilization process;
- failure to establish and follow written procedures designed to prevent microbiological contamination of drug products purporting to be sterile;
- aseptic processing areas are deficient regarding the system for monitoring environmental conditions;
- failure to thoroughly review any unexplained discrepancy, whether or not the batch has already been distributed;
- failure to exercise appropriate controls over computers or related systems to assure that changes in master production and control records or other records are instituted only by authorized personnel; and
- failure of the written stability program for drug products to include reliable, meaningful, and specific test methods.